The European Medicines Agency (EMA) has agreed on principles for involving patients and consumers under the age of 18 in the activities of its scientific committees and working parties.
Young patients and consumers can make an important contribution to EMA’s committee discussions on medicines by sharing their experience and perspectives of living with a disease or condition.
These working principles set out best practice for the interaction between scientific committees or working parties and young people under 18 years old, for example, discussion in small groups, provision of specific support, use of appropriate language, etc. They also address issues such as obtaining parental consent, protection of personal data and the privacy of the young patients.
The principles define what input young people could contribute and suggest options on how best to capture their opinions. The document also establishes a process for identifying, supporting and consulting with young people.